A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety, and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety, and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Albusomatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Apr 2016 Status changed from active, no longer recruiting to discontinued as per the Business decision.
    • 02 Mar 2016 Planned End Date changed from 1 Feb 2018 to 1 Apr 2016 ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top